Zogenix shares down 23% after FDA refuses to review company’s marketing application for seizure drug
April 09, 2019 at 12:26 PM EDT
Shares of Zogenix, Inc. plunged 23% Tuesday after the company disclosed Monday evening that the Food and Drug Administration had refused to review the marketing application for a treatment of seizures associated with a rare form of childhood epilepsy.